Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accounts Payables (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Accounts Payables for 12 consecutive years, with $1.6 million as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables fell 23.8% year-over-year to $1.6 million; the TTM value through Mar 2026 reached $1.6 million, down 23.8%, while the annual FY2025 figure was $1.3 million, 347.22% up from the prior year.
  • Accounts Payables hit $1.6 million in Q1 2026 for Cartesian Therapeutics, up from $1.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $3.2 million in Q4 2023 and bottomed at $214000.0 in Q3 2022.
  • Average Accounts Payables over 5 years is $1.2 million, with a median of $693000.0 recorded in 2022.
  • On a YoY basis, Accounts Payables climbed as much as 971.91% in 2024 and fell as far as 90.86% in 2024.
  • Cartesian Therapeutics' Accounts Payables stood at $316000.0 in 2022, then soared by 896.84% to $3.2 million in 2023, then crashed by 90.86% to $288000.0 in 2024, then soared by 347.22% to $1.3 million in 2025, then grew by 24.07% to $1.6 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $1.6 million, $1.3 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.